DE3856121T2 - Amyloid-Peptide - Google Patents

Amyloid-Peptide

Info

Publication number
DE3856121T2
DE3856121T2 DE3856121T DE3856121T DE3856121T2 DE 3856121 T2 DE3856121 T2 DE 3856121T2 DE 3856121 T DE3856121 T DE 3856121T DE 3856121 T DE3856121 T DE 3856121T DE 3856121 T2 DE3856121 T2 DE 3856121T2
Authority
DE
Germany
Prior art keywords
amylin
kcntat
found
peptides
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3856121T
Other languages
English (en)
Other versions
DE3856121D1 (de
Inventor
Garth James Smith Cooper
Anthony Charles Willis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of DE3856121D1 publication Critical patent/DE3856121D1/de
Application granted granted Critical
Publication of DE3856121T2 publication Critical patent/DE3856121T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE3856121T 1987-04-27 1988-04-27 Amyloid-Peptide Expired - Lifetime DE3856121T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878709871A GB8709871D0 (en) 1987-04-27 1987-04-27 Peptides

Publications (2)

Publication Number Publication Date
DE3856121D1 DE3856121D1 (de) 1998-03-05
DE3856121T2 true DE3856121T2 (de) 1998-07-23

Family

ID=10616392

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3856121T Expired - Lifetime DE3856121T2 (de) 1987-04-27 1988-04-27 Amyloid-Peptide

Country Status (9)

Country Link
EP (1) EP0289287B1 (de)
JP (3) JP2766647B2 (de)
AT (1) ATE162802T1 (de)
CA (1) CA1341333C (de)
DE (1) DE3856121T2 (de)
ES (1) ES2114522T3 (de)
GB (1) GB8709871D0 (de)
GR (1) GR3026640T3 (de)
HK (1) HK1003033A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
EP0348490B1 (de) * 1988-01-11 1995-09-27 Amylin Pharmaceuticals, Inc. Behandlung von diabetes mellitus typ 2
US5405831A (en) * 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
WO1991000737A1 (en) * 1989-07-10 1991-01-24 Amylin Corporation Treatment of obesity and essential hypertension and related disorders
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
EP0503827A1 (de) * 1991-03-15 1992-09-16 Pfizer Inc. Verwendung von Amylin und Calcitonin-Genverwandten Peptiden und Antagonisten davon
WO1992020367A1 (en) * 1991-05-24 1992-11-26 Amylin Pharmaceuticals, Inc. Treatment of anorexia and related states
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
DE69333683T2 (de) * 1992-05-15 2005-10-27 Amylin Pharmaceuticals, Inc., San Diego Antikörper-testbesteck zur bestimmung von amylin
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0717635B1 (de) * 1993-09-07 2000-11-15 Amylin Pharmaceuticals, Inc. Methoden zur regulation der den magen und darm betreffenden motilitaet
EP1553078A1 (de) 1994-10-21 2005-07-13 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
EP0910578A2 (de) * 1996-01-19 1999-04-28 The Board Of Regents, The University Of Texas System Rekombinante expression von proteinen mittels sekretorischer zellinien
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
DE69739388D1 (de) * 1996-05-01 2009-06-10 Nps Pharma Inc Inorganische am Ionen-Rezeptor aktive Verbindungen
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
US6821954B2 (en) * 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AU2001293557A1 (en) * 2000-09-19 2002-04-02 University Of Toronto New inhibitors of iapp fibril formation and uses thereof
US8168233B2 (en) 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
ATE471340T1 (de) 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US20080004211A1 (en) * 2004-02-23 2008-01-03 Paul Fraser Inhibitors of Amyloid Fibril Formation and Uses Thereof
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20090215069A1 (en) * 2004-07-28 2009-08-27 Andreas Christ Pancreatic polypeptide as target/marker of beta cell failure
EP2127676A3 (de) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Behandlung von Fettleibigkeit und mit Fettleibigkeit zusammenhängenden Erkrankungen und Störungen
ATE439140T1 (de) 2005-03-31 2009-08-15 Amylin Pharmaceuticals Inc Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
JP5312054B2 (ja) 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー／エス アミリンとインスリンの混合物
US8815541B2 (en) * 2009-11-25 2014-08-26 Novo Nordisk A/S Method for making polypeptides
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
US9475866B2 (en) * 2012-09-12 2016-10-25 Neurimmune Holding Ag Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
WO2015196174A1 (en) 2014-06-20 2015-12-23 Greene Howard E Infusion delivery devices and methods
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE500044C2 (sv) * 1985-02-15 1994-03-28 Gambro Lundia Ab Peptidförening, antiserum framställt med användning av denna förening samt användning av föreningen
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus

Also Published As

Publication number Publication date
DE3856121D1 (de) 1998-03-05
EP0289287A2 (de) 1988-11-02
EP0289287A3 (de) 1990-05-30
JP2766647B2 (ja) 1998-06-18
EP0289287B1 (de) 1998-01-28
GB8709871D0 (en) 1987-06-03
JPH10168099A (ja) 1998-06-23
JPH09133679A (ja) 1997-05-20
HK1003033A1 (en) 1998-09-30
ATE162802T1 (de) 1998-02-15
ES2114522T3 (es) 1998-06-01
JPS6463594A (en) 1989-03-09
CA1341333C (en) 2002-01-22
GR3026640T3 (en) 1998-07-31

Similar Documents

Publication Publication Date Title
ATE162802T1 (de) Amyloid-peptide
EP0208491A3 (en) Hybrid polypeptides and process for their preparation
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
DE3879204T2 (de) Alkylierungs-/transalkylierungsverfahren zur selektiven herstellung von monoalkylierten aromatischen kohlenwasserstoffen.
HUT46638A (en) Process for producing 1,1,1-trifluoro-2,2-dichloroethane in the presence of hydrogen fluoride catalyst
IL62553A0 (en) Vectors comprising dna sequences and methods for producing recombinant dna molecules and cloning vectors
IL70414A (en) Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
PT73259A (en) Process for preparing novel substituted pyrazinyl-1,2,4-oxadiazole-5-ones
ZA859437B (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
DE3885366D1 (de) Verfahren zur Herstellung von Pyrrolo-(3,4-c)pyrrolen.
EP0294028A3 (en) Fluoxetine useful for the treatment of diabetes
DE69233005D1 (de) DNA kodierend für Propylendopeptidase und dessen Verwendung
HUT47136A (en) Process for producing cyclic peptides with anticoagulant effect
HK1013951A1 (en) Production and use of anthelmintic agents and protective immunogens
EP0712928A3 (de)
DE3888386D1 (de) Verfahren zur Herstellung von Proteinen.
PT87857A (pt) Process for the preparation of novel immunossupressant peptides
HUT53125A (en) Process for producing peptides with anticoagulant activity
EP0146903A3 (de) Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
HK65497A (en) CDNAs encoding somatotropin expression vectors and hosts
EP0281089A3 (en) Process for the preparation of factor viii:c deficient plasma, and deficient plasma obtained therwith
PT73587A (en) Process for preparing novel peptides
CS168087A1 (en) Process for the concentration of 1-methoxy-2-propanone in mixtures thereof with 1-methoxy-2-propanolom
DE3851214T2 (de) Verfahren zur Herstellung von flachen Vorrichtungen zum Pumpen von Sauerstoff.
CS753786A1 (en) Process for the determination of /2,5-dioxo-4-imidazolidinyl/-urea in the presence of iodine complex with polyvinylpyrolidone

Legal Events

Date Code Title Description
8364 No opposition during term of opposition